Business Wire

Takeda Reports 3rd Quarter FY2017 Results

Del

Takeda Pharmaceutical Company Limited (TOKYO:4502):

Underlying Revenue growth +6.7% led by Takeda's Growth Drivers

  • Underlying Revenue grew +6.7% year-to-date, with Takeda's Growth Drivers (Gastroenterology, Oncology, Neuroscience and Emerging Markets) posting strong underlying revenue growth of +14.5%.
    • Gastroenterology +23.7% fueled by market share growth of ENTYVIO® and TAKECAB®.
    • Oncology +13.8% driven by the expansion of NINLARO® and ADCETRIS®, and the addition of revenue from ICLUSIG® and ALUNBRIG®.
    • Neuroscience +26.4% led by robust growth of TRINTELLIX® in the U.S.
    • Emerging Markets +1.9% with strong performance in Russia and Brazil offsetting temporary declines in China and the Middle East.
  • Underlying Revenue performance was driven by double-digit growth in the U.S. (U.S. +17.0%, Japan +1.3%, Europe & Canada +4.9%).
  • Reported revenue grew +4.1%, with the positive contribution from Takeda's Growth Drivers and favorable currency impact (+3.4pp) more than offsetting the negative impact of divestitures (-5.9pp).

Double-digit EPS growth reflecting strong revenue growth and progress of Global Opex Initiative

  • Underlying Core Earnings grew +32.8%, reflecting strong revenue growth and margin step-up of 3.9pp (+2.3pp gross margin; +1.6pp from OPEX margin).
  • Reported operating profit was up +48.2%, driven mainly by Core Earnings growth. It also includes one-time gains of 136.9 billion yen, including the sale of shares held in Wako Pure Chemical Ltd., disposal of real estate, and the transfer of additional long-listed products to Teva Takeda Yakuhin Ltd.
  • Underlying Core EPS was up +25.8%, and reported EPS increased +45.5% to 309 yen per share.

Net leverage improved due to steady progress on cash flow

  • Year-to-date Operating Free Cash Flow increased +25.1% to 152.1 billion yen, and the disposal of non-core assets generated an additional 142.9 billion yen of cash.
  • Net Debt / EBITDA dropped to 1.9x from 2.7x in March 2017.

James Kehoe, Chief Financial Officer, commented:
"Our Growth Drivers continued to power ahead and, together with our cost management initiatives, led to double-digit earnings growth and significant margin expansion. We are updating our full year guidance to reflect higher Velcade sales, and we now project Core Earnings margin expansion of approximately 300bps. Takeda will continue to deliver value to patients and shareholders as we execute against our key mid-term priorities of growing the portfolio, rebuilding the pipeline, and boosting profitability."

Reported Results for Q3 YTD (April - December) FY2017

(billion yen)  

FY2016
Q3 YTD

 

FY2017
Q3 YTD

  % Growth vs Prior Year
Reported   Underlying 2
Revenue 1,315.8 1,369.6 +4.1% +6.7%
Core Earnings1 228.3 292.7 +28.2% +32.8%
Operating Profit 217.4 322.3 +48.2% -
Net Profit3 165.7 240.9 +45.4% -
EPS   212 yen   309 yen   +45.5%   +25.8%

1

  Core Earnings is calculated by deducting SG&A expenses and R&D expenses from reported Gross Profit. In addition, certain other items that are non-core in nature and significant in value may also be adjusted.

2

Underlying growth compares two periods of financial results on a common basis, showing the ongoing performance of the business excluding the impact of foreign exchange and divestitures.

3

Attributable to the owners of the company.
 

FY2017 Management Guidance: Raising full year underlying guidance to reflect higher Velcade sales;
now projecting Core Earnings growth in the "high twenties"

    Previous Guidance (growth %)
(Nov 1, 2017)
  Revised Guidance (growth %)
(Feb 1, 2018)
Underlying Revenue Low single digit Mid single digit
Underlying Core Earnings High teen High twenties
Underlying Core EPS Mid teen Mid twenties
Annual Dividend per Share   180 yen   180 yen
 

FY2017 Reported Forecast: Raising revenue & profit forecast to reflect Velcade upside;
EPS growth now at 36.9%. Forecast includes impacts from US Tax Legislation and Teva JV impairment

(billion yen)   Previous Forecast
(Nov 1, 2017)
 

Revised Forecast
(Feb 1, 2018)

  vs. FY2016
Revenue 1,720.0 1,745.0 +0.7%
Core Earnings 267.5 289.5 +18.1%
Operating Profit 200.0 218.7 +40.3%
Net Profit 152.0 157.3 +36.9%
EPS 195 yen   201 yen   +36.9%  
Exchange Rate (annual average)   1 US$=112 yen

1 euro=129 yen

  1 US$=112 yen

1 euro=130 yen

   
 

For more details on Takeda's FY2017 3rd quarter results and other financial information, please visit https://www.takeda.com/investors/reports/

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.

Contact information

Investor Relations
Takeda Pharmaceutical Company Limited
Takashi Okubo, +81-(0)3-3278-2306
takeda.ir.contact@takeda.com
Media Relations
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi, +81 (0)3-3278-2095
kazumi.kobayashi@takeda.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Mavenir Wins 5G Asia “Best RAN Product” Award24.9.2018 13:00Pressemelding

Mavenir, focused on transforming mobile network economics for Communications Service Providers (CSPs), is proud to be awarded 5G Asia’s 2018 ‘Best RAN Product’ award for its innovative, flexible Cloud RAN solution. Mavenir’s Cloud RAN can save operators 37% in total cost of ownership (TCO) over a five-year period due to a 49% reduction in capex and a 31% annual reduction in opex1. The TechXLR8 5G Asia Awards were announced on September 19th in Singapore and celebrate excellence in the APAC’s technology and telecommunications community with the goal of showcasing the year’s greatest industry achievements. Mavenir’s Cloud RAN extends virtualization of the network to the edge and provides strategic differentiation by enabling the remote radio units (RRUs) to interwork with the virtualized cloud base band unit (vBBU) over ethernet fronthaul (FH) to the xRAN specification published early this year. Combined with network slicing support and flexibility for the vBBU to be co-located with the

ARTMS’ QUANTM Irradiation System™ to Be Featured at Two International Conferences in September24.9.2018 13:00Pressemelding

ARTMS Products, Inc. announced today that it has been invited to present at the National Nuclear Security Administration’s 2018 Mo-99 Topical Meeting on Tuesday, September 25th and the Third International Symposium on Technetium and other Radiometals in Chemistry and Medicine on Thursday, September 27th. Joel Kumlin will present at the 2018 Mo-99 Topical Meeting in Knoxville, TN, during Session 7, Production Projects and Technologies II, at 13:00EDT on September 25th. Mr. Kumlin will be discussing progress on implementation of the ARTMS QUANTM Irradiation System™ for producing technetium-99m. The QIS™ combines local production control and a cost-effective, easy-to-use solid target system for the production of Tc-99m on most cyclotron systems. ARTMS recently announced that the QIS™ received CE mark approval and has been installed in a number of countries throughout the world. ARTMS also announced that Dr. Paul Schaffer, CTO, has been invited to present at the Third International Symposi

Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C24.9.2018 12:30Pressemelding

Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will launch at a list price of $24,000 for the most common course of therapy and will be available in January 2019. Since the launch of Gilead’s first HCV medication in 2013, the average price paid for each bottle of medicine in the United States has decreased by more than 60 percent off of the public list prices, across health insurers and government payers. Due to the complexity and structure of the U.S. healthcare system, however, these discounts provided by Gilead may not always translate into lower costs for patients. Further, existing contracts, together with laws associated with government pricing policies, make it cha

GSMA To Showcase Mobile’s Increasing Impact on Sustainable Development During UN General Assembly Week24.9.2018 12:00Pressemelding

The GSMA will represent the global mobile industry at the 73rd session of the UN General Assembly (UNGA) being held in New York this week, advancing the leading role the sector is playing in meeting the UN Sustainable Development Goals (SDGs). Over the coming week, the GSMA will be participating in a wide range of activities with several high-profile partners and providing a critical platform for dialogue between mobile industry leaders, heads of state, global leaders and governments to further accelerate mobile’s contribution to the SDGs. “The GSMA will be in UNGA for the third year running to demonstrate how the global mobile industry is strengthening its commitment to improving lives around the world, as we enter a critical period in the delivery of the UN’s ambitious 2030 Agenda,” said Mats Granryd, Director General of the GSMA. “As the leading forum for international political cooperation, UNGA give us a unique opportunity to showcase how mobile’s unprecedented global scale is con

BolySolar Announcing Launch of BolySolar Tree24.9.2018 11:00Pressemelding

Bolymedia Holdings Co. Ltd., a global high-tech company headquartered in Silicon Valley, is pleased to announce its fifth patented renewable energy product – BolySolar Tree - at the Anaheim, California SPI to be held on September 24-27, 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005050/en/ BolySolar Tree (Graphic: Business Wire) BolySolar is a complete set of solar technologies and products that will revolutionize the entire energy industry. At SPI this month, the company will be showcasing its fifth product from its growing line of solar technologies - the BolySolar Tree. The diagram shows the basic design of the BolySolar Tree. The basic idea of the BolySolar Tree is to allow double-sided solar energy utilization with the help of mirrors, thereby reducing solar energy system costs and generating electricity for a longer duration. Compared to the conventional fixed-mount PV panel systems or tracker-mounted P

The 9th Edition of Tour of China 2018 Comes to an End24.9.2018 10:45Pressemelding

The sixteen-day Tour of China 2018 is concluded in Anshun, Guizhou Province on 23rd September, as the 13th stage witnesses the victory of Jakub Mareczko from Wilier Triestina – Selle Italia. The last stage in Anshun is a circuit race of 127.8 kilometers with two sprints and one KOM of Category 4. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005421/en/ The riders are crossing the finishing line. (Photo: Business Wire) The stage remained exciting and unpredictable due to little difference between riders’ results after the 12th stage. No rabbit group was formed even after 40 kilometers, though riders had never stopped breaking out from the peleton since race started. As the peleton kept its pace, Luke Mudgway from H&R Block Pro Cycling Team led the rabbit group of four who worked together quite well, with the gap of 1 minute 50 seconds. The gap narrowed, however, as the peleton started to chase with 30 kilometers to go,